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The choice of intervention, between open surgery
and an endovascular procedure, can be difficult, often
weighing risks to life and limb against each other in an
attempt to save both. There are risks to limb and life
involved in any attempted revascularisation proce-
dure, particularly in some difficult surgical bypasses,
but patients with CLI have complex lesions not suit-
able for endovascular treatment, and amputation has
the same risk. Accurately predicting the result of a
particular revascularisation in an individual is diffi-
cult based on available literature. The assessment of
chances of success in an individual case would be bet-
ter based on the audited results obtained in the rele-
vant institution rather than published results from
other centres (see p 5220). It is important to develop
guidelines regarding the likelihood of success below
which a reconstruction should not attempted.
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D 4.11
General Issues Relating to Surgical Treatment
04.11.1
Anaesthesia
Either general or regional anaesthesia may be used for
lower-extremity bypass grafts. Some centers advocate
the use of a combination of both techniques for aortic
surgery for optimal patient comfort and minimal res-
piratory depression. There have been reports of
increased distal graft patency when epidural/spinal
anaesthesia are used. However, the results of a recent
randomised control trial failed to show any effect of
the type of anaesthesia on the 30-day patency rate of
infrainguinal bypass grafts.'
The choice and conduct of the anaesthetic technique
is more important in the transabdominal aortoiliac
reconstructions. All inhalation anaesthetics are
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myocardial depressants; intravenous narcotic anal-
gesics such as fentanyl are often used as an alternative
to inhalation anaesthetics because they produce mini-
mal myocardial depression. However, large doses of
narcotics may be necessary to avoid hypertension dur-
ing intraabdominal procedures, and as a consequence
may produce ventilatory depression. Spinal or epidur-
al anaesthesia has no direct effect on the myocardium
but may increase myocardial oxygen consumption
because they may be associated with hypertension
and bradycardia resulting from sympathetic blockade.
Prospective studies that have compared general and
epidural anaesthesia have found no advantage to
either technique in reducing perioperative cardiac
complications in patients undergoing aortic surgery or
infrainguinal procedures.s-' Systemic anticoagulation
is not a contraindication for epidural anaesthesia if
begun after catheter placement, although it is uncer-
tain how long a delay is necessary after catheter place-
ment before anticoagulation can be instituted.'
04.11.2
Antibiotic Prophylaxis for Vascular Procedures
It is generally believed that graft contamination occurs
most commonly at the time of the original operation.
This emphasises the importance of a meticulous ster-
ile technique with avoidance of skin contact by the use
of adherent plastic drapes. Several randomised stud-
ies have now demonstrated the efficacy of antibiotic
prophylaxis in reducing the incidence of vascular graft
infection, and its perioperative use is now well accept-
ed.5,6 There is evidence that antibiotic prophylaxis
should continue until drains and invasive monitoring
lines are removedP The same principles of sterile
techniques must apply to endovascular procedures
with stent implantation, evidence that the same prin-
ciples should apply to stents. Covered stents should
be treated as prosthetic grafts in terms of use of pro-
phylactic antibiotics. However, the need for and effec-
tiveness of antibiotic prophylaxis with other endovas-
cular techniques is unknown.8,9,lO,ll
Recommendation 94: Use of prophylactic antibi-
otics with prosthetic grafts
Patients undergoing prosthetic grafts should have
prophylactic antibiotic therapy perioperatively.
Critical Issue 36: Duration of prophylactic antibi-
otics with prosthetic grafts
There is a need for more data to determine how
long antibiotic prophylaxis is required when pros-
thetic grafts are implanted.
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D 4.11.3
Perloperative Care of the Diabetic Patient
Ideally, blood sugar should be normalised in the dia-
betic patient before surgical intervention. This may
involve the switch from oral agents to insulin in some
patients. The control of sepsis in the diabetic foot may
help control hyperglycaemia and ketoacidosis.
Particular attention to the renal function is needed in
patients with diabetes, because investigations such as
angiography may lead to deterioration. The rationale
for striving to achieve near-normal glucose has been
established, but other factors must be considered in
patients with diabetes who must undergo surgery
with less than optimal control of metabolism in an
acute situation. Such patients can be haemodynami-
cally unstable during anaesthesia because of dehydra-
tion and osmotic shifts. Furthermore, such patients are
more prone to infection, have decreased wound heal-
ing, and may have increased free fatty acids, the
metabolism of which increases myocardial oxygen
consumption.w>
D 4.11.4
Treatment of the Failing Graft
The concept of the "failing graft" has been emphasised
by several series documenting improved results when
intervention is directed at the time when the graft is
still patent, that is, failing rather than failed. Graft sur-
veillance is necessary to detect a failing graft at this
preocclusive stage. The details are dealt with in D 4.14,
Surveillance After Revascularisation (p 5214). Grafts
may fail on the basis of intrinsic graft pathology or
pathology in the inflow or outflow segments. Inflow
and outflow lesions should be managed according to
the principles outlined elsewhere in this document.
Graft stenoses can be managed by either interposition
or jump graft segmental bypass or patch angioplasty,
depending on the length of the lesion. Debate contin-
ues, but current opinion favours segmental bypass or
patch angioplasty rather than percutaneous balloon
angioplasty for most lesions.
D 4.11.5
Treatment of Graft Thrombosis: The Failed Graft
The choice between thrombolysis and thrombectomy
for graft occlusion is complicated by the fact that
these tend to be linked with PTA and surgical revas-
cularisation, respectively, in trials. As a result of this
and also of a significant technical failure rate, four
major trials have failed to show an overall advantage
for thrombolysis on an intent-to-treat basis.1U 5,16,17
However, its obvious potential advantages (stated
previously) and the relative ease of the procedure
probably can be achieved only by selective applica-
tion. Although urgent thrombectomy may be
required for immediate limb threat, and surgical
reconstruction is preferred in delayed occlusions
(>14 days' duration), thrombolysis holds the advan-
tages in terms of mortality and amputation for less
than 14 days' occlusion.w'? This complex subject
is dealt with in more detail in C 4.2.2,
Contraindications to Thrombolysis, p 5130.
Open surgical procedures have been the tradition-
al approach for bypass graft occlusion, directing pro-
cedures at thrombectomy, and revision or replace-
ment of the existing graft, with the latter giving best
results.18•19,20 Thrombolysis ha s been advocated as a
less invasive, alternative means of restoring graft
function that also provides the opportunity to
unmask stenotic lesions responsible for the occlusive
event and to clear the run-off vessels.21,22 The
unmasked lesion is then addressed with an endovas-
cular or operative approach after successful throm-
bolysis, the choice depending on the characteristics
of the lesion (eg, neointimal hyperplasia or diffuse or
local atherosclerotic involvement). The most appro-
priate treatment for a valve cusp stenosis is operative
patching or resection and reconstruction. The results
for open repair are believed to be superior to dilata-
tion and yield excellent secondary patency rates,23 If.
the distal anastomosis is involved or should there be
progression of disease, there may be a need to extend
the bypass graft. Whatever method is used, good
success rates have been achieved with the use of
alternative vein sources.> If an established bypass
graft fails less than 6 months after construction, then
graft replacement of this disadvantaged conduit is
indicated.e'
Recommendation 95: Treatment of chronic critical
leg ischaemia due to bypass graft occlusion
In patients with chronic critical leg ischaemia, sur-
gical revision or graft replacement is the preferred
treatment for bypass graft occlusion. Thrombolysis
may be considered as a treatment option in patients
who present early after their bypass graft occlusion
where the limb is not immediately threatened.
The treatment strategy for bypass graft occlusion
must be tailored to the clinical setting and the risks
and benefits associated with the therapeutic options.
In addition to the characteristics of the underlying
lesion, the parameters that are important in deterrnin-
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ing appropriate therapy include the severity of the
patients' symptoms, the duration of the occlusion, and
the nature of occluded conduit (autogenous or pros-
thetic). For instance, in patients with occluded lower-
limb grafts who present with sudden-onset claudica-
tion, the clinician will need to consider the original
indications for the graft and possible future surgical
options if no attempt is made to rescue the graft.
D 4.11.6
General Complications of Surgical Intervention
Cardiac mortalityand morbidity
The most common source of morbidity and mortality
after revascularisation for PAD is myocardial
ischaemia. Although operative mortality is decreasing
steadily, long-term survival of these patients continues
to be compromised. The cumulative long-term sur-
vival is 40% to 50% at 10 years. Patients with CLI,
extensive arterial disease, or diabetes have a less
favourable long-term prognosis than patients with
localised disease and claudication. Most late deaths
are also attributed to atherosclerotic heart disease.v
(see A 2.7, Fate of Patients With CLI, P 521). Other spe-
cific complications are outlined in the following para-
graphs.
Deep vein thrombosis
A randomised prospective trial of deep venous throm-
bosis (DVT) prophylaxis in aortic surgery failed to
show any increased incidence after aortic surgery in
Table 52. Complication of aorto-iliac bypass grafts
the control group compared with the prophylaxis
group." A second study reported a DVT incidence of
9.8% in patients undergoing either aortic or distal
revascularisation (with the highest incidence follow-
ing arnputatlonj.v All patients in this study had
received DVT prophylaxis. Therefore, although phar-
macotherapy to avoid arterial thrombosis after revas-
cularisation also frequently reduces the risk of DVT,
this risk cannot be neglected entirely.
D 4.11.7
Complications of Aortoiliac Reconstruction
Currently, excellent early and late results of direct aor-
toiliofemoral reconstructions for occlusive disease can
be anticipated. Perioperative mortality rates are well
under 3% in many centres, and patency rates of close
to 85% at 5 years and 75% at 10 years are expected.e>
Though somewhat dated, a list of complications of
aortoiliac reconstruction other than graft failure are
summarised in Table 52.
Acute complications; limb ischaemia
Acute limb ischaemia occurring shortly after aortic
operation for occlusive disease is generally attributa-
ble to acute thrombosis of the graft or one of its limbs
and occurs in 1% to 3% of patients. The main causes
are twisting, kinking of the graft limb, or technical
problems at the distal femoral anastomosis site. Acute
limb ischaemia also can occur as a result of intraoper-
ative thromboembolic events, all related to technique
and all preventable.
Complication
Myocardial InfarctionJO,3!
DeathJ2,33.:H,35.36,37.J8
Intestinal ischaemia'?
Renal failure.a·" ··2.'3
Ureteral injury! '
Spinal cord ischaemia;5."
Graft infection"·" ·"
Aortoenteric fistula ' 7.-IS
Lymph fistula'?
False aneurysmI7" ~,5C,5! ,52
Altered sexual function"
Incidence (%)
0.8-5.2
0-3.3
1.1
0--4.6
1.6
0.25
0.1-1.3
0.1-0.5
1.5-3.5
3-5
20
Aetiology/Commenls
Concurrent cardiac disease
Usually myocardial
Ligation IMA--<:olonic
Preexisting SMA disease
Preexisting renal dysfunction increases risk
Frequent association with graft complication
Atheroernboli, occlusion vascular supply
Higher incidence involving groin anastomosis
Erosion, lack of reperitonealisat ion,
aortic false aneurysms
Divis ion of lymphatics
Infect ion, native artery degenerat ion
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Intesiina! ischaemia
Intestinal ischaemia is more likely after aortic surgery
for aneurysmal disease than after that for PAD but
may occur after the latter. A large or meandering infe-
rior mesenteric artery (IMA) with upward flow warns
of concomitant coeliac or superior mesenteric artery
(SMA) disease deserving attention and mandates IMA
preservation. Otherwise, preservation of hypogastric
internal iliac artery outflow is the key to avoiding
intestinal ischaemia, impotence, or paraplegia (see
next paragraphj.e As discussed earlier, this may dic-
tate the choice between proximal end-to-side and end-
to-end anastomosis.
Erectile impotence
The incidence of iatrogenic erectile impotence after
aortic reconstruction may approach 25%. Most often,
impotence implies inadequate preservation of the
hypogastric artery and pelvic circulation.
Retrograde ejaculation is also a frequent occurrence
and is attributable to disturbance of autonomic
nerve fibres that course along the left wall of the
aorta and cross the common iliac arteries. As
described by De Palma et al,54 a nerve-sparing
approach to the infrarenal aorta is helpful, and
preservation of the hypogastric artery flow by a vari-
ety of techniques is also essential.
Anastomotic false a11eunJsms
The incidence of anastomotic false aneurysm forma-
tion after aortoiliac reconstruction varies from 1% to
5% and is by far most common at the femoral anasto-
mosis." Previously these were related to the use of silk
sutures and, rarely, prosthetic suture material may
fracture. Degenerative changes within the host arteri-
al .wall leading to weakness and dehiscence of the
intact suture line appear to be the most common
cause. Infection may be a contributing cause and
always needs to be considered as a possible causative
factor,>
The true incidence of proximal aortic anastomotic
aneurysm may be higher than previously thought
after aortic surgery for PAD; a study by Edwards et
a157 reported a 10% incidence, of mostly asymptomatic
anastomotic aneurysms, at a mean interval of 12 years
after initial revascularisation. These anastomotic aor-
tic aneurysms are more common after lateral anasto-
mosis than after end-to-end anastomosis. This sug-
gests that CT scans should be a routine part of the late
follow-up of patients with an aortic graft, that is,
beginning at 3 years postintervention.
Aortoiliac, aortofemoral graft infection
The incidence of graft infection is between 1% and 5%
after aortic surgery. It may be difficult to prove
unequivocally that a graft is infected. Despite this, all
efforts should be made to determine whether a peri-
graft collection is present, whether graft infection is
likely, and which infecting organisms are involved.
Once this has been determined, the likelihood of infec-
tion must be balanced against the general condition of
the patient, the extent of revision surgery, and the
necessity for immediate intervention.
The organisms most commonly isolated from blood
or from wounds are Pseudomonas, Staphylococcus,
and streptococcus species. Computed tomography
scanning and magnetic resonance imaging are very
helpful in demonstrating fluid collections around a
suspect aortic graft. Labelled white cell scans also can
be useful if performed more than 4 weeks after sur-
gery. Treatment of aortic graft infection is challenging.
Graft conservation with local debridement of infected
tissue followed by local irrigation with antibiotics has
been advocated by some authors.v
However, many authors believe that most graft
infections involve the whole length of the prosthesis,
even though presentation or imaging may suggest a
local sepsis. Graft excision has been recommended by
most authors. This decision should be made carefully,
and, whenever possible, the patient's condition needs
to be optimised before surgery-? After excision, exten-
sive retroperitoneal debridement must be done. A
number of recent reports have advocated direct in situ
replacement with a rifampin-soaked Dacron or PTFE
graft. However, these selected exceptions to the gener-
ally accepted policy of complete graft excision and
extraanatomic bypass primarily involve late indolent
infections with Staphylococcus epidermidis with little
associated systemic sepsis. Placement of a graft in a
site that is potentially infected might result in higher
risk of future reinfection.v
Autogenous vein grafts provide an alternative to
prosthetic material for in situ reconstruction, but suffi-
cient vein is difficult to obtain, and this technique is
not practised widelye! However, recently good experi-
ences have been reported with the use of the superfi-
cial femoral vein for this purpose, because size mis-
match is less of a problem.62•63 The consequences of
harvesting this vein have been surprisingly mild.s'
Cryopreserved homografts to reconstruct the aortoili-
ac anatomy have recently been advocated for replace-
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ment of infected aortic prosthetic grafts. Concern
regarding long-term dilatation remain, although they
seem resistant to reinfection.s'
When complete graft excision with extraanatomic
reconstruction using bilateral axillounifemoral
bypasses is not feasible because of extensive
groin/thigh sepsis or previous extraanatomic bypass
failure, in situ reconstruction using (superficial
femoral or popliteal) veins may be the only remaining
option. However, because of its significant mortality
and morbidity, it is reserved for situations in which
life or limb loss would probably result without revas-
cularlsatlon.s- 6-l, 65,66 Some experience has been
achieved using in situ allograft replacernent/"
D 4.11.8
Complications of Infrainguinal Vein Bypass Grafting
(Table 53)
WOlllld complications
The in situ technique has a recorded wound complica-
tion rate of 10% to 30%, with most problems occurring
in the distal wound or the mid thigh.74,75 Meticulous
dissection without creation of flaps and tension-free
closure are emphasised to reduce this complication. A
retrospective comparative study showed that the in
situ technique was associated with a higher rate of
wound complications than nonreversed or reversed
subcutaneously placed long saphenous vein grafts
(23% vs. 9.3%). A continuous incision was also associ-
ated with higher rates of wound complications.v A
prospective randomised trial, however, failed to con-
firm this difference in wound complications seen
in situ (15%) and reversed vein (17%) graft reconstruc-
tions.e?
Table 53. Complications of infrainguinal bypass
Arteriooenous fistula
These are avoided by on table graft assessment
(angiogram, Doppler assessment) but occasionally
become apparent after the operation. Arteriovenous
fistulae may be treated by ligation or embolisation
under local anaesthetic.
Legstoelling
Leg swelling after revascularisation is an accepted
complication of any infrainguinal bypass, The origin
of the swelling has been investigated and found to be
related to the lymphatic disruption and interruption
in the groin along the path of vein harvest and
increased lymph production during postoperative
reactive hyperaemla.w?
Earlygraft occlusion
Early failure rates have been reported to be as high as
17% for grafts to the popliteal artery and 24% for
grafts to more distal arteries and is related to technical
failure (eg, missed valve cusp, twist, anastomotic
error).78,79,50,81 In 63% of the graft failures in one study,
the cause was intrinsic to the graft or anastomosls.v
Early graft thrombosis is usually attributed to techni-
cal error, hypercoagulable state, or periods of
hypotension or hypoperfusion. A randomised trial
reported the benefit of Dextran 40 in preventing early
graft thrombosis of "difficult" distal bypasses.v The 1-
week occlusion rate was 20.5% in the control group
and 6.9% (0% in vein grafts) in the Dextran 40 group.
The overall early graft occlusion rate can be reduced
by good technique, intraoperative monitoring of the
Complication
Death6S·b9
Myocardial infarction6S.l4
Wound:
Veinb9.7F5
Prosthetic"
Exposure/blowout'?
Infection:
Vein71
PTFE/Dacron 71
HUV71
Leg oedema'?
Lymph leak~9.73
Acute limb ischaemia
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Incidence (%)
1.3-6
1.9-3.4
10-30
18
9.5/1.6
1.36
3.56
1.48
50-100
0.5-1.8
1-2
Aetiology/ comments
Usually cardiac
Resolution usually by 4 months
Lower with femoral distal than with
aortofemoral
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completed bypass, and adjuvant therapy (see 0 4.13,
Adjuvant Therapy After Revascularisation p 5209;
04.14, Surveillance After Revascularisation, p 5214).
Haeniodunamic failure
This may be said to occur when limb viability is
threatened or not reversed even in the face of a patent
bypass graft. Occasionally, limb loss may occur
despite a patent graft. The current objective criteria for
haernodynamic failure is failure to increase the ABPI
or toe:brachial index more than 0.10.83
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D 4.12
General Issues Relating to Endovascular
Treatment
D 4.12.1
Need for Surveillance
As with surgical bypass grafts, it is likely that surveil-
lance and repeat intervention would improve the
assisted primary patency of PTA. In infrainguinal
PTA, primary and assisted primary patency rates
approximate each other because re-intervention is
attempted in a relatively small proportion of PTA
patients.J.2.3,4 For example, Gallino et al' repeated PTA
on only 14% of failed or failing femoropoliteal PTA
whereas Capek et aP reported a re-intervention rate of
only 8%.4 However, when repeat PTA is performed in
a higher percentage of patients, patency can be
Table 5-1: Ideal characteristics of stents and delivery systems
Characteristics
improved. For example, Harris et a15, in a series of PTA
performed by surgeons, used surveillance and re-
intervention as needed with 57% primary 6-month
patency and 82% assisted primary 6-month patency.
Although the ability of periprocedural duplex to
predict ultimate PTA durability is controversial.v"
duplex ultrasound may be useful in an appropriate
longitudinal postprocedure surveillance program.
Vroegindewij et al? found that duplex ultrasound is
sensitive in detecting restenosis and, along with
clinical and other noninvasive follow-up, it could
be very useful in augmenting the durability of
femoropopliteal PTA.
D 4.12.2
Comparison of Available Stents
Currently all intravascular stents in clinical use are
permanent and metallic. Stent designs and technolo-
gies used for managing peripheral vascular disease
arc continually evolving. The availability of and
approved indications for specific stents vary by coun-
try. The ideal stent and delivery system should have
the following characteristics'wu-P:
Stents are generally stratified into balloon-expand-
able (eg, Palrnaz, Strecker) and self-expandable. The
self-expandable stents are generally based on one of
two designs: (1) spring-open expansion after removal
of restraint (eg, Wallstent) or (2) thermal memory
expansion at body temperature (eg, Memotherm,
Nitinol stents). Currently thermal stents are construct-
ed of Nitinol (nickel-titanium alloy), and self-expand-
Allow for efficiency in and ease of deployment
Use percutaneous technique
- have a low-profile delivery system
- have a high expansion ratio
Be available in a wide range of diamet ers and lengths
Have longitudinal flexibility
Ability to be optimally and precisely positioned
- have high rad io-opacity
- have minim al foreshortening
. - ability to be retr ieved or repositioned
- no slippage of stent on balloons; rupture-resistant balloon (for stent/balloon delivery system)
Yield durable clinical results
Reliably oppose elastic recoil, stenosis, or dissection flap
Be thromboresistant
Resist restenosis
Resist comp ression , deformation, or fracture
Bebiologically compatible, to resist infection and minimise inflammatory reaction
Be incorporated into vessel wall with thin neointima/functional endothelium
Do not emboli se or migrate
Be inexpensive
Allow for noninvasive imaging and follow-up with CT, MRA, and ultrasound.
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